𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Physicochemical heterogeneity of hepatitis B e antigen detected in asymptomatic carriers and carriers in a hemodialysis unit

✍ Scribed by Ei Yamada; Hitoshi Ohori; Nakao Ishida


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
602 KB
Volume
4
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Physicochemical studies of hepatitis B e antigen (HBeAg) revealed a clear cut difference between e1 and e2 antigen. The e1 antigen was found to have a MW of Ca 150,000 and a pI of 6.4-7.2, whereas both the MW and pI of the e2 antigen were heterogeneous depending upon the source of serum. Sera obtained from asymptomatic carriers were characterized by low titers of HBs antigen, HBc antigen and DNA polymerase and contained e2 antigen of larger molecular weight (200,000-300,000) with a narrow distribution range and a pI of 4.8 to 5.2 (type 1). On the other hand, the sera from patients in a hemodialysis unit who were HBs antigen carriers and had high titers of HBs antigen, HBc antigen and DNA polymerase contained e2 antigen of heterogeneous distribution in MW (from 300,000 to 70,000) and pI (type 2 and 3). The e2 antigen obtained from the higher MW type 3 serum had lower isoelectric points (pI 4.5 to 5.2) as was the case with e2 antigen obtained from asymptomatic carriers whereas relatively wide range of isoelectric points (pI 5.1 to 8.2) was found with the lower molecular weight e2 antigen.


πŸ“œ SIMILAR VOLUMES


Foscarnet therapy in chronic hepatitis B
✍ V. G. Bain; H. M. Daniels; A. Chanas; G. J. M. Alexander; Dr. Roger Williams πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 343 KB πŸ‘ 2 views

Foscarnet (trisodium phosphonoformate) is a novel antiviral agent that inhibits viral-specific DNA polymerase. In the present study, eight males with chronic HBV carriage (HBeAg and HBV-DNA seropositivity >I2 months) showing chronic persistent hepatitis (CPH) or chronic active hepatitis (CAH) on liv

Epidemiology of hepatitis b e antigen an
✍ Ghanshyam Lohiya; Sunita Lohiya; Vinh Trong Ngo; Ramona Crinella πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 264 KB πŸ‘ 2 views

Screening for HBeAg and anti-HBe WM performed on 133 carriers of HBsAg in an institution for the mentally retarded. By radioimmunoassay, the prevalences of HBeAg and anti-me were determined to be 16 and 78%, respectively. J3BeAg prevalence WM significantly different in the following pairs of carrier

Evolution of precore/core promoter mutat
✍ Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Prof. Jia-Horng Kao; Ding-Shinn Chen πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 154 KB πŸ‘ 1 views

## Abstract The evolution of precore stop codon mutation (A1896) and dinucleotide mutation (T1762/A1764) in the basic core promoter (BCP) of hepatitis B virus (HBV) genome during transient seroconversion and seroreversion of hepatitis B e antigen (HBeAg) remains unclarified. Five HBeAg‐positive HBV